Revolution Medicines Inc. — Sponsor Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

5 Recruiting

3 Completed trials

12 Countries active

15 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase I

Phase I (Other)

Phase III: 3 Phase II: 2 Phase I/II: 1 Phase I: 1 Phase I (Other): 2

Oversight events:

3 temporary halts across 1 trial

View oversight register →

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 6 Colorectal cancer 1 Ductal adenocarcinoma of pancreas 1

Top IMPs

(12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE 6 (2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE 2 CARBOPLATIN 2 CISPLATIN 2 PEMBROLIZUMAB 2 PEMETREXED 2 RMC-6291 1

All trials

9 total

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 304) Pending

2025-523495-23-00 Phase III 4 countries (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPER…
Study of zoldonrasib with or without daraxonrasib and other anticancer drugs in patients with RAS G12D-mutant non-small cell lung cancer (NS… Recruiting

2025-521147-21-00 Phase II 9 countries (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPER…
Study of Daraxonrasib (RMC-6236) in Patients with RAS Mutated NSCLC Recruiting

2024-518154-16-00 Phase III 8 countries (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPER…
Study of RMC-6291 and RMC-6236 With Other Anti-Cancer Agents in Patients With RAS G12C-Mutated NSCLC - Subprotocol A Recruiting

2023-509571-16-00 Phase I (Other) 5 countries (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPER…
A study of RMC-6236 in combination with pembrolizumab in participants with nonsmall cell lung cancer with certain mutations -Subprotocol B Recruiting

2023-509572-42-00 Phase I (Other) 5 countries (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPER…
Dose Escalation and Dose Expansion Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Patients with Advanced … Recruiting

2023-508178-27-00 Phase I/II 5 countries
Study of zoldonrasib in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC) Ended

2025-521681-10-00 Phase II 9 countries (2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL…
Phase 3 study of RMC-6236 in patients with previously treated metastatic PDAC Ended

2024-516063-89-00 Phase III 4 countries (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPER…
Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mut… Ended

2024-511548-19-00 Phase I 5 countries

Showing 1–9 of 9 trials

← All sponsors A–Z